

Yotaro Kudo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9905351/publications.pdf>

Version: 2024-02-01

18
papers

1,340
citations

687363

13
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

2718
citing authors

#	ARTICLE	IF	CITATIONS
1	Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 63, 131-140.	3.7	538
2	Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. <i>Cancer Science</i> , 2012, 103, 670-676.	3.9	241
3	CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. <i>Gut</i> , 2018, 67, 1493-1504.	12.1	131
4	Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBP β . <i>Carcinogenesis</i> , 2014, 35, 2404-2414.	2.8	83
5	Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 61469-61484.	1.8	64
6	A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. <i>Scientific Reports</i> , 2016, 6, 23899.	3.3	60
7	Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. <i>Journal of Hepatology</i> , 2011, 55, 1400-1408.	3.7	57
8	Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	33
9	Inhibition of histone methyltransferase G9a attenuates liver cancer initiation by sensitizing DNA-damaged hepatocytes to p53-induced apoptosis. <i>Cell Death and Disease</i> , 2021, 12, 99.	6.3	19
10	Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation. <i>Scientific Reports</i> , 2019, 9, 18859.	3.3	18
11	TET1 upregulation drives cancer cell growth through aberrant enhancer hydroxymethylation of HMGA2 in hepatocellular carcinoma. <i>Cancer Science</i> , 2021, 112, 2855-2869.	3.9	18
12	MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages. <i>Gastroenterology</i> , 2022, 162, 1272-1287.e16.	1.3	16
13	A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks. <i>Journal of Gastroenterology</i> , 2016, 51, 711-721.	5.1	15
14	Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. <i>Scientific Reports</i> , 2020, 10, 21194.	3.3	14
15	Immunomodulation by Inflammation during Liver and Gastrointestinal Tumorigenesis and Aging. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2238.	4.1	13
16	Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2021, 56, 456-469.	5.1	11
17	Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 695-705.	2.0	9
18	Abstract PO-067: A multi-omics study in patient-derived organoids reveals MNX1-HNF1B axis to be indispensable for intraductal mucinous papillary neoplasm lineages. , 2021, , .		0